LONDON (Alliance News) - Drug development company Evgen Pharma said Wednesday that it has secured a European patent recognising its intellectual property for a method of stabilising sulforaphane, the lead compound in the company's cancer treatment drug SFX-01.
The European patent is set to expire in 2028.
"This patent grant is timely from a commercial perspective as we are moving close to the announcement of our first Phase II clinical data from SFX-01, which we continue to expect in the first half of this year as part of our ongoing STEM trial in breast cancer," Chief Executive Steve Franklin said.
Shares in the drug development company were trading 5.3% higher at 18.95 pence.
